NCT07218341 2026-04-17
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Eli Lilly and Company
Phase 4 Recruiting
Clinical Trials
38 trialsNCT06651970 2026-04-15
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
AstraZeneca
Phase 4 Recruiting
NCT05160922 2026-03-30
Crizotinib Continuation Clinical Study
Pfizer
Phase 4 Active not recruiting
NCT04726501 2026-03-19
CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma
Children's Cancer Group, China
Phase 4 Active not recruiting
NCT07474961 2026-03-16
BLOOD-dose
Rigshospitalet, Denmark
Phase 4 Not yet recruiting
NCT06049134 2026-03-09
Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
M.D. Anderson Cancer Center
Phase 4 Active not recruiting
NCT06035757 2026-03-03
The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery
Konkuk University Medical Center
Phase 4 Recruiting
NCT06289673 2026-03-03
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
St. Jude Children's Research Hospital
Phase 4 Recruiting
NCT06876649 2026-03-02
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Eli Lilly and Company
Phase 4 Recruiting
NCT06876662 2026-03-02
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Eli Lilly and Company
Phase 4 Recruiting
NCT06831370 2026-02-23
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
Takeda
Phase 4 Recruiting
NCT07426484 2026-02-23
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Dana-Farber Cancer Institute
Phase 4 Not yet recruiting
NCT02844309 2026-02-11
BDH-WM02
Institute of Hematology & Blood Diseases Hospital, China
Phase 4 Completed
NCT02844322 2026-02-11
BDH-WM01
Institute of Hematology & Blood Diseases Hospital, China
Phase 4 Completed
NCT02844361 2026-02-11
BDH-WM03
Institute of Hematology & Blood Diseases Hospital, China
Phase 4 Completed
NCT02858804 2026-02-11
BDH-MCL01
Institute of Hematology & Blood Diseases Hospital, China
Phase 4 Completed
NCT05170399 2026-02-05
Vaccine Responses in Patients With B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 4 Recruiting
NCT07167862 2026-01-23
PPPOCUS
University of California, Irvine
Phase 4 Not yet recruiting
NCT07355699 2026-01-21
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
Beijing Tongren Hospital
Phase 4 Recruiting
NCT07320534 2026-01-08
Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase
Gadjah Mada University
Phase 4 Not yet recruiting
NCT04091009 2025-12-31
Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine/Naloxone in the Perioperative Period on Pain Control and Post-Operative Opioid Use Disorder Symptoms
Massachusetts General Hospital
Phase 4 Withdrawn
NCT06752850 2025-12-19
A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis
Swedish Orphan Biovitrum
Phase 4 Active not recruiting
NCT07169331 2025-12-19
A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia
BeOne Medicines
Phase 4 Recruiting
NCT07270146 2025-12-08
Effectiveness and Safety of Guilu Erxian Oral Liquid in the Treatment of Oligozoospermia and Asthenospermia With Syndrome of Shen (Kidney) Essence Deficiency
DongE E Jiao Coporation Limited
Phase 4 Completed
NCT07270835 2025-12-08
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
The First Affiliated Hospital of Soochow University
Phase 4 Recruiting
NCT07264894 2025-12-04
ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial
Zhengzhou University
Phase 4 Not yet recruiting
NCT05687032 2025-12-03
A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Pfizer
Phase 4 Completed
NCT03229200 2025-10-30
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Pharmacyclics Switzerland GmbH
Phase 4 Active not recruiting
NCT01909934 2025-09-19
Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Takeda
Phase 4 Completed
NCT05442554 2025-09-18
A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma
Takeda
Phase 4 Completed
NCT06285370 2025-09-18
A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy
Kyowa Kirin Co., Ltd.
Phase 4 Active not recruiting
NCT07016165 2025-08-22
Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies
Gadjah Mada University
Phase 4 Recruiting
NCT04460235 2025-07-01
HEMATOVAC
Poitiers University Hospital
Phase 4 Recruiting
NCT03190330 2025-05-25
A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion
Johnson & Johnson Private Limited
Phase 4 Completed
NCT04042376 2025-05-25
A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)
Janssen Research & Development, LLC
Phase 4 Completed
NCT04506086 2025-05-18
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 4 Terminated
NCT06956092 2025-05-02
Glofitamab
Zhengzhou University
Phase 4 Not yet recruiting
NCT05071482 2025-05-01
Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 4 Terminated